Kansas Patent of the Month – February 2024
Evogen, Inc. is at the forefront of revolutionizing epilepsy diagnosis and treatment with its groundbreaking invention, EvoScore™. This blood-based diagnostic test is designed to identify measurable changes in select proteins following seizures, providing a rapid and accurate means of diagnosing epilepsy.
The recently patented method involves contacting blood samples with antibodies targeting specific biomarkers associated with inflammation and seizures. These biomarkers include thymus and activation-regulated chemokine (TARC), interleukin (IL)-7, monocyte chemotactic protein (MCP)-4, and several others. By measuring the concentrations of these biomarkers and comparing them to controls, EvoScore effectively identifies patients in need of epilepsy treatment.
One unique aspect of EvoScore is its ability to predict both acute and chronic changes in patients with seizures and epilepsy. The predictive algorithm, EvoScore Predictive Models, combines protein levels to generate a diagnostic score. This score serves as a reliable indicator for ruling in or ruling out seizures and epilepsy. The method allows for monitoring patients over time and throughout treatment, enabling personalized medicine approaches.
Epilepsy, affecting over 2.3 million patients in the U.S. and 65 million worldwide, poses a significant burden on healthcare systems. Current diagnostic protocols often involve lengthy and expensive processes, including EEGs and video EEGs. EvoScore addresses this challenge by offering a cost-effective blood test that can be performed at any time, providing timely and accurate diagnosis.
EvoScore addresses the critical issue of over- or under-treatment by identifying patients with suspected seizures due to underlying conditions other than epilepsy. This breakthrough invention not only improves diagnostic accuracy but also has the potential to significantly reduce healthcare costs associated with epilepsy care.
Evogen’s EvoScore represents a paradigm shift in epilepsy diagnosis, offering a reliable, accessible, and timely solution for patients and healthcare providers. As the field of epilepsy research advances, EvoScore™ stands as a beacon of innovation, bringing hope and improved outcomes to millions of individuals affected by this neurological disorder.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
